Agenus | AGEN - Assets


Agenus reported $186.46M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Agenus USD 186.46M 40.34M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Celldex Therapeutics USD 511.25M 71.73M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Incyte USD 7.34B 381.14M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 200.89B 1.68B Mar/2026
Jiangsu Hengrui CNY 71.29B 1.43B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Merck EUR 53.07B 1.54B Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Northwest Biotherapeutics USD 30.61M 1.06M Sep/2025
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.44B 30.38M Mar/2026